A report in The New York Times has revealed that cancer
drug Avastin may not be the wonder drug it was previously believed to be. Currently Avastin, or bevacizumab, is
approved by the U.S. Food and Drug Administration for treating advanced lung
and breast cancer.
Dr. Leonard Saltz, a colon cancer specialist at Memorial
Sloan-Kettering Cancer Center in New York told the NYT that the benefits of
Avastin may be less than what was believed.
Avastin is costly with a year's dose racking up $100,000.
Barbara Brenner, executive director of advocacy group
Breast Cancer Action feels that there is a need for public discussion before recommending
Avastin for wider use.